ABUS vs LYB · P/E 5.4, rev $6.2M vs P/E 21, rev $40.30B
Arbutus Biopharma Corp (ABUS) versus LyondellBasell Industries NV (LYB) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
LyondellBasell Industries NV (LYB) is a specialty chemicals company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LYB revenue for 2024-12-31 was $40.30B. Net income was $1.37B. Revenue was down 2.0% from 2023-12-31 to 2024-12-31. LYB currently screens at market cap $19.93B and trailing P/E 21.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LYB currently screens at market cap $19.93B and trailing P/E 21.5.
Not investment advice. Open the ABUS and LYB stock pages for the full models.
Not investment advice.